NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
12.28
+0.30 (2.50%)
Sep 5, 2025, 3:20 PM - Market open
NovoCure Employees
NovoCure had 1,488 employees as of December 31, 2024. The number of employees increased by 35 or 2.41% compared to the previous year.
Employees
1,488
Change (1Y)
35
Growth (1Y)
2.41%
Revenue / Employee
$423,495
Profits / Employee
-$114,886
Market Cap
1.37B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,488 | 35 | 2.41% |
| Dec 31, 2023 | 1,453 | 133 | 10.08% |
| Dec 31, 2022 | 1,320 | 153 | 13.11% |
| Dec 31, 2021 | 1,167 | 144 | 14.08% |
| Dec 31, 2020 | 1,023 | 241 | 30.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NVCR News
- 8 days ago - Novocure Announces Upcoming Investor Events - Business Wire
- 11 days ago - Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain - Business Wire
- 16 days ago - Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer - Business Wire
- 5 weeks ago - NovoCure's Wearable Oncology Edge And Compelling Valuation - Seeking Alpha
- 5 weeks ago - Top 3 Health Care Stocks That May Explode In July - Benzinga
- 5 weeks ago - NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Novocure Reports Second Quarter 2025 Financial Results - Business Wire
- 2 months ago - Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025 - Business Wire